Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.65 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PYGM | P11217 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884569 | 0.91 | MAPK14 (0.77) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1880731 | 0.88 | MAPK14 (0.51) | MAPK14MAPKAPK2LCKCYP2C9CYP2C19 | |
| SCHEMBL3637436 | 0.87 | MAPK14 (0.82) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1881709 | 0.83 | MAPK14 (0.76) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1880113 | 0.81 | MAPK14 (0.67) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3671610 | 0.79 | MAPK14 (1.00) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1879780 | 0.79 | MAPK14 (0.47) | MAPK14MAPKAPK2LCKCYP2C9CYP2C19 | |
| SCHEMBL1880265 | 0.74 | MAPK14 (0.73) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1881812 | 0.73 | MAPK14 (0.76) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1886774 | 0.73 | MAPK14 (0.66) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367671-B2 | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents | AMGEN INC. (US) | 2013-02-05 | — | — | US | claimed |
| US-20110105499-A1 | Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | claimed |
| WO-2009117156-A1 | PYRAZOLO-PYRAZINONE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2009-09-24 | — | — | WO | claimed |
| US-8367671-B2 | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents | AMGEN INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110105499-A1 | Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2009117156-A1 | PYRAZOLO-PYRAZINONE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105499-A1 | Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof | MAPK1, MAP3K1, MAP4K2 | MAPK14 32/4885MAPKAPK2 28/4885MAPK13 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.